ELTX: Symmetrical Triangle detected on 26 Feb 2026

ELTX is forming a symmetrical triangle with excellent structural quality (15.0/15), currently trading at $10.98 between resistance at $9.16 and support at $8.95. The pattern shows strong breakout potential (13.0/13) with solid volume confirmation (12.0/12), supported by an 88.0 overall score and 76.75% win probability. The stock has rallied 32.93% over one month, now testing upper bounds. RSI at 73.98 signals overbought conditions, while MACD histogram remains positive at 0.1952, suggesting momentum persistence despite technical exhaustion.

Elicio Therapeutics, a clinical-stage biotech focused on immunotherapy, has not released major news catalysts recently available through public sources. The stock's 138.7% gain from 52-week lows and strong sector momentum (Healthcare regime score 0.95) reflect broad biotech strength and potential optimism around pipeline development. The company operates in the competitive immunotherapy space where clinical trial readouts and partnership announcements typically drive volatility. Broader sector bullish regime (0.62) supports continued upside if pipeline developments progress positively. Recent institutional positioning or insider activity would be critical context for validating this pattern's strength.

A successful breakout above $9.16 resistance would project a measured move target of $11.63 (conservative estimate), representing approximately 6% upside from current price. Volume confirmation is critical—breakout should occur on volume above the 142K 20-day average (current volume 169K shows 1.19x ratio, adequate but not commanding). Invalidation occurs if price closes below $8.95 support, negating the pattern structure entirely. The 76.75% historical win probability suggests favorable odds, but overbought RSI (73.98) increases risk of short-term pullback before resuming upside.

Critical risks include: (1) RSI at 73.98 indicates extreme overbought conditions, historically preceding 5–10% pullbacks in biotech names; (2) ELTX shows 138.7% gain from 52-week lows—extended rally vulnerable to profit-taking; (3) As a clinical-stage biotech with no major revenue driver, stock is entirely dependent on trial readouts or partnership news—any negative clinical data would collapse this setup violently; (4) ATR volatility at 7.47% suggests outsized daily swings typical of small-cap biotech; (5) Low beta (0.37) masks that micro-cap biotech stocks exhibit sector-specific event risk independent of market correlations; (6) Lack of recent catalysts in public record raises question of what's driving current momentum—without fundamental anchors, pattern is vulnerable to momentum exhaustion.